Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.
企業コードDNA
会社名Ginkgo Bioworks Holdings Inc
上場日Apr 19, 2021
最高経営責任者「CEO」Dr. Jason Kelly
従業員数834
証券種類Ordinary Share
決算期末Apr 19
本社所在地27 Drydock Avenue
都市BOSTON
証券取引所NYSE Consolidated
国United States of America
郵便番号02210
電話番号18774425362
ウェブサイトhttps://investors.ginkgobioworks.com/
企業コードDNA
上場日Apr 19, 2021
最高経営責任者「CEO」Dr. Jason Kelly
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし